This biotech is targeting the 'immortality switch' to fight blood cancers
Harnessing Nobel Prize-winning insights on telomeres, Geron’s CEO Dr. John A. Scarlett is taking on some of hematology’s toughest challenges—and winning FDA backing in the process.
NVIDIA’s Biggest Bet Yet: How Recursion Is Powering a New Era of AI-Driven Drug Discovery
“Almost all of the data that we use comes from our own laboratories - data generation doing real experiments in human biology… The AI side of things will be commoditized eventually, and the winners will be those who have the strongest data moat in life sciences.”
From Grammys to Gene Therapy: Gaurav Shah’s Rocket-Fueled Revolution in Rare Diseases
A Grammy-winning CEO is taking gene therapy to new heights.
Is neuromodulation the breakthrough that Alzheimer's has been waiting for?
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
What are GLP-1 agonists and how valuable are they?
GLP-1 is quickly becoming one of the most famous hormones in the world.
Under The Microscope: The Basics of Cell and Gene Therapy
Genomics is seeing its golden age in the clinic. How did we get here?
Wearable diagnostics: Continuous Glucose Monitoring Devices
How do they work, and how big is the market?
Announcing Vital Signs in Fortune
We will publish our in-depth healthcare report, Vital Signs, in Fortune magazine on December 1, 2024. Vital Signs: Future of Healthcare will appear in Fortune ahead of one of the most important events in the industry: JPM Week, the annual healthcare conference hosted by J.P. Morgan at the Westin
The 3 Biggest Biotech Events in 2025
We expect the attendance for each to be well over 20,000 in 2025.